Development and current use of in hematopoietic stem cell transplantation in children and adolescents in Poland: Report of the Polish pediatric study group for hematopoietic stem cell transplantation of the Polish society for pediatric oncology and hematology - PubMed

Affiliations

• PMID: 29880247
• DOI: 10.1016/j.transci.2018.05.012

Review

Development and current use of in hematopoietic stem cell transplantation in children and adolescents in Poland: Report of the Polish pediatric study group for hematopoietic stem cell transplantation of the Polish society for pediatric oncology and hematology

Jacek Wachowiak et al. Transfus Apher Sci. 2018 Jun.

Abstract

The purpose of the survey was to evaluate the development and current use of hematopoietic stem cell transplantation (HSCT) in Poland between 1989-2016. The data for analysis (indication, number of performed HSCT, HSCT type, donor type, and stem cell source, year) have been collected annually using a standardized form. In Poland, between 1989-2016, the number of pediatric transplant beds grew from one to 40 and number and rate of transplants increased annually from 1/year (0.8/10 million) to 186/year (248/10 million). During the analyzed time period 2506 HSCTs were performed, including 1718 (68.6%) allogeneic transplants (allo-HSCT) with142 in 2016 and 788 (31.4%) autologous transplants (auto-HSCT) with 44 in 2016. Among 1718 allo-HSCT, 74% were performed for malignancy (ALL 47.2%, AML 26.2%, MDS 10.8%, CML 8.1%, NHL/HD 6.1%, others 2.5%), and 26% for non-malignant disorders (SAA 41%, congenital immunodeficiencies 35.4%, hereditary bone marrow failure 16%, metabolic disorders 7%). Among 788 auto-HSCTs, 30.8% were done for hematological malignancy (NHL 41.2%, AML 23.9%, HD 17.7%, ALL 15.6%, other 1.5%), while the remaining 69.2% for solid tumors (neuroblastoma 59.8%, Ewing's sarcoma 20.4%, other 19.8%). In Poland, between 1989-2016, the infrastructure indispensable to perform HSCT in every child with indication for this therapeutic procedure was created, and HSCT became an important part of pediatric treatment, especially in pediatric oncology, hematology, and in primary immunodeficiencies.

Keywords: Adolescents; Children; Hematopoietic stem cell donor; Hematopoietic stem cell source; Hematopoietic stem cell transplantation (HSCT); Indications for HSCT.

Similar articles

• Haematopoietic stem cell transplantation in children in eastern European countries 1985-2004: development, recent activity and role of the EBMT/ESH Outreach Programme.

  Wachowiak J, Labopin M, Miano M, Chybicka A, Stary J, Sterba J, Masszi T, Labar B, Maschan A, Kowalczyk JR, Lange A, Holowiecki J, Kalman N, Afanassiev BV, Dini G; EBMT Paediatric Working Party. Wachowiak J, et al. Bone Marrow Transplant. 2008 Jun;41 Suppl 2:S112-7. doi: 10.1038/bmt.2008.68. Bone Marrow Transplant. 2008. PMID: 18545232

• Bacterial infections in pediatric hematopoietic stem cell transplantation recipients: incidence, epidemiology, and spectrum of pathogens: report of the Polish Pediatric Group for Hematopoietic Stem Cell Transplantation.

  Zając-Spychała O, Wachowiak J, Pieczonka A, Siewiera K, Frączkiewicz J, Kałwak K, Gorczyńska E, Chybicka A, Czyżewski K, Jachna-Sawicka K, Wysocki M, Klepacka J, Goździk J, Zaucha-Prażmo A, Kowalczyk JR, Styczyński J. Zając-Spychała O, et al. Transpl Infect Dis. 2016 Oct;18(5):690-698. doi: 10.1111/tid.12581. Epub 2016 Sep 23. Transpl Infect Dis. 2016. PMID: 27479544

• Hematopoietic stem cell transplantation in the Eastern Mediterranean Region (EMRO) 2011-2012: A comprehensive report on behalf of the Eastern Mediterranean Blood and Marrow Transplantation group (EMBMT).

  Aljurf M, Nassar A, Hamidieh AA, Elhaddad A, Hamladji RM, Bazarbachi A, Ibrahim A, Ben Othman T, Abdel-Rahman F, Alseraihy A, Fahmy O, Hussein AA, Alabdulaaly A, Adil S, Alkindi SS, Bayoumy M, Dennison D, Bekadja MA, Redhouane AN, Rasheed W, AlSagheir A, Alsudairy R, Ladeb S, Benchekroun S, Ramzi M, Ahmed P, ElSolh H, Ahmed SO, Hussain F, Ghavamzadeh A. Aljurf M, et al. Hematol Oncol Stem Cell Ther. 2015 Dec;8(4):167-75. doi: 10.1016/j.hemonc.2015.09.002. Epub 2015 Oct 1. Hematol Oncol Stem Cell Ther. 2015. PMID: 26452331

• The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China-recommendations from the Chinese Society of Hematology.

  Xu L, Chen H, Chen J, Han M, Huang H, Lai Y, Liu D, Liu Q, Liu T, Jiang M, Ren H, Song Y, Sun Z, Wang J, Wu D, Zhou D, Zou P, Liu K, Huang X. Xu L, et al. J Hematol Oncol. 2018 Mar 2;11(1):33. doi: 10.1186/s13045-018-0564-x. J Hematol Oncol. 2018. PMID: 29495966 Free PMC article. Review.

Cited by

• The impact of NKG2A and NKG2D receptors and HLA-E and MICA ligands polymorphisms on post-transplant complications after paediatric allogeneic HSCT: a single-centre experience.

  Siemaszko J, Ussowicz M, Rybka B, Ryczan-Krawczyk R, Kałwak K, Bogunia-Kubik K. Siemaszko J, et al. Front Genet. 2023 Jun 7;14:1186123. doi: 10.3389/fgene.2023.1186123. eCollection 2023. Front Genet. 2023. PMID: 37351346 Free PMC article.

• Impact of early chimerism status on clinical outcome in children with acute lymphoblastic leukaemia after haematopoietic stem cell transplantation.

  Lejman M, Zaucha-Prażmo A, Zawitkowska J, Mroczkowska A, Grabowski D, Kowalczyk JR, Drabko K. Lejman M, et al. BMC Cancer. 2019 Nov 26;19(1):1141. doi: 10.1186/s12885-019-6360-3. BMC Cancer. 2019. PMID: 31771553 Free PMC article.

Publication types

MeSH terms

LinkOut - more resources

• Full Text Sources

  • ClinicalKey
  • Elsevier Science

• Other Literature Sources

  • scite Smart Citations

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal